Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical studies with mazindol

S Inoue1

  • 1Division of Geriatric Health and Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.

Obesity Research
|November 1, 1995
PubMed
Summary
This summary is machine-generated.

Mazindol, an appetite suppressant, aids in long-term weight loss and maintenance, improving obesity-related health markers. It also enhances very-low-calorie diet (VLCD) effectiveness and helps manage weight gain in Prader-Willi syndrome.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Purification and amino-acid sequence of a nerve growth factor from the venom of Vipera russelli russelli.

Biochimica et biophysica acta·1992
Same author

Fish egg glycophosphoproteins have species-specific N-linked glycan units previously found in a storage pool of free glycan chains.

The Journal of biological chemistry·1992
Same author

Successful pancreatojejunal anastomosis for pancreatoduodenectomy.

Surgery, gynecology & obstetrics·1992
Same author

QRS complex changes in the V5 ECG lead during cardiac surgery.

Journal of cardiothoracic and vascular anesthesia·1992
Same author

[Autonomic function and severity of hypertrophic cardiomyopathy by power spectrum analysis on heart rate variability].

Kokyu to junkan. Respiration & circulation·1992
Same author

Stimulation of glucose transport by guanine nucleotides in permeabilized rat adipocytes.

Biochemical and biophysical research communications·1992
Same journal

Gastric bypass as treatment for obesity: trends, characteristics, and complications.

Obesity research·2006
Same journal

Tanner staging of secondary sexual characteristics and body composition, blood pressure, and insulin in black girls.

Obesity research·2006
Same journal

Stability of the association between birth weight and childhood overweight during the development of the obesity epidemic.

Obesity research·2006
Same journal

Trends in height and BMI of 6-year-old children during the nutrition transition in Chile.

Obesity research·2006
Same journal

Body weight and health status: importance of socioeconomic position and working conditions.

Obesity research·2006
Same journal

Predictors of long-term weight maintenance.

Obesity research·2006
See all related articles

Area of Science:

  • Pharmacology
  • Endocrinology
  • Obesity Research

Background:

  • Mazindol is an anorexiant medication available in Japan.
  • It functions by stimulating beta-adrenergic receptors and modulating hypothalamic centers involved in feeding and satiety.

Purpose of the Study:

  • To evaluate the efficacy of mazindol in long-term weight management.
  • To assess mazindol's role in maintaining weight loss after very-low-calorie diet (VLCD) therapy.
  • To investigate the combined effects of mazindol with VLCD and its impact on Prader-Willi syndrome.

Main Methods:

  • Long-term administration of mazindol.
  • Assessment of body weight, appetite, and obesity-related disease markers.
  • Evaluation of weight maintenance post-VLCD with and without mazindol.

Related Experiment Videos

  • Analysis of mazindol's effects in Prader-Willi syndrome patients.

    • Main Results:

    • Average weight reduction of 6.8 kg with long-term mazindol use.
    • Appetite suppression in 59% of subjects; improvements in blood pressure, liver enzymes, lipids, and glucose tolerance.
    • Significantly higher weight maintenance post-VLCD when mazindol was used (53.3% vs. 20.0%).
    • Mazindol enhanced VLCD efficacy in outpatients and inhibited weight gain in two Prader-Willi syndrome patients.

    Conclusions:

    • Mazindol demonstrates positive effects on weight reduction, appetite control, and metabolic parameters.
    • It is effective in maintaining weight loss after VLCD therapy and shows promise for Prader-Willi syndrome.
    • While beneficial, the overall effects of mazindol were noted as limited.